buyModerate cluster of 4
Qasim Iftikhar Ahmad bought $27k of IOBT
Chief Medical Officer at IO Biotech, Inc.. 31,350 shares at an average of $0.85, traded Dec 23, 2024, filed Dec 26, 2024.
Conviction score
43Value
$27k
31,350 shares
Holdings after
31,350
change unknown
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +5Trade size$27k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000905148-24-003414, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 23, 2024 | POpen-market purchase Common Stock | +31,350 | $0.85 | $27k | 31,350 | Dec 26, 2024 |
Related signals
Other insiders at IO Biotech, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | IOBTbuy IO Biotech, Inc. | Heidi Hunter director | $21k 15,000 shares | - | |
| 40Moderate | IO Biotech, Inc. | Devin Whittemore Smith General Counsel | $9,720 12,000 shares | +243% | |
| 40Moderate | IO Biotech, Inc. | Amy Sullivan Chief Financial Officer | $8,483 10,250 shares | +14% | |
| 46Moderate | IO Biotech, Inc. | Mai-Britt Zocca Chief Executive Officer | $10k 12,500 shares | +33% | |
| 22Weak | IOBTsell IO Biotech, Inc. | Novo Holdings A/S owner | $99k 75,000 shares | -2% | |
| 39Weak | IOBTsell IO Biotech, Inc. | Novo Holdings A/S owner | $802k 658,809 shares | -13% | |
| 42Moderate | IOBTsell IO Biotech, Inc. | Novo Holdings A/S owner | $988k 658,809 shares | -11% | |
| 25Weak | IOBTbuy IO Biotech, Inc. | Brian Burkavage Chief Accounting Officer | $10k 10,000 shares | +667% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.